glp 1 thyroid cancer Does Using GLP-1 Drugs, Like Zepbound or Wegovy, Increase Your Risk of Cancer? Taking GLP‑1 Without Diabetes in

"This approval for Ozempic allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated," remarked Anna Windle, head of clinical development, medical, and regulatory affairs at Novo Nordisk

Our healthcare professionals will assess your situation, discuss your weight loss objectives, and provide personalized recommendations based on your needs and goals

Novo Nordisk filed its New Drug Application with the FDA on 18 December 2025, based on data from the REDEFINE 1 trial

95% CI, 0.61-3.63 and RR, 1.92

These key announcements underscore the continued transformation of the metabolic disease landscape, where innovation is increasingly focused on efficacy, accessibility and patient adherence

Magnitude of Risk: The absolute risk of vision-threatening progression remains 9 % or long-standing diabetes